What is ARA 290?

ARA 290, also known as cibinetide, is an 11–amino acid peptide that has potent tissue-protective and tissue-regenerative properties. It is called “nonhematopoietic peptide” because ARA 290 exerts its beneficial effects without stimulating erythropoesis or red blood cell production. Preclinical and clinical studies have shown that by selectively interacting with the innate repair receptor, ARA 290 mediates tissue protection.

Cibinetide is a linear nonhematopoietic peptide that mimics the three-dimensional structure of the helix B surface domain of erythropoietin (EPO).  Cibinetide binds selectively to the non-hematopoietic EPO receptor (the innate repair receptor, IRR), which is a heterodimer of the EPO receptor and the cytokine family beta common receptor (βCR, CD131). 

The IRR becomes locally upregulated following tissue injury and its activation initiates a local anti-inflammatory response, inhibition of death signal and anti-apoptosis, preventing overt tissue damage.  Cibinetide produces effective and long-term pain relief following peripheral nerve damage, an effect mediated by its anti-inflammatory and immunomodulatory functions, and the IRR is thought to be a point of integration between the immune system and pain signalling via nociception.  Cibinetide possesses analgesic and tissue protective effects in many diseases such as diabetes and cancer.

Research and the role of ARA 290.

ARA 290 Is a derivative of erythropoietin (EPO).

1、In vivo, ARA 290 (0.8 and 8 nmol / kg, intraperitoneal injection) reduces plasma creatine, urea, and aspartate transaminase (AST) levels (markers of renal dysfunction) in a rodent model of renal ischemia-reperfusion injury. It reduced the wound area in a rat model of dermal injury caused by perforation biopsy and a rat model of bedsore ulcers.

2. In a rat model of cortical impact-induced traumatic brain injury (TBI), ARA 290 (30 µ g / kg, intraperitoneal injection) shortened the delay in finding a platform in the Morris water maze.

3. It can also reduce the tactile abnormal pain in the rat model of neuropathic pain caused by spinal cord nerve injury (SNI)

Chemical Structure of ARA 290

molecular formula:   C 51 H 84 N 16 O 21 • XC 2 H 4 O 2

Structure:Glp-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH (Glp is pyroglutamic acid)

Features of the ARA 290

Solubility:> 50 mg per ml in water

Appearance:Freeze dried solid

Storage:Store dry, frozen and in the dark

Purity:>98% by hplc

Potential Benefits of ARA 290

  • Promotes tissue repair
  • Relieves neuropathic pain
  • Fights diabetes
  • Boosts immune function

The amount of ARA 290 used

Recommended daily subcutaneous injection of 0.33 mL 4 mg/mL of ARA-290 solution (i. e. 1.32 mg daily) for a total of 30 days. Some people with more severe pain take 4 mg a day.

Associated Side Effects of ARA 290

  • Elevated blood pressure
  • Fast heart rate